Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer

Area of Science:

• Endocrinology
• Oncology
• Bone Metabolism

Background:

• Androgen deprivation therapies (ADT) for prostate cancer accelerate osteoporosis and increase fracture risk.
• Transdermal estradiol has emerged as a potential alternative to ADT for managing prostate cancer.
• The impact of transdermal estradiol on bone mineral density (BMD) in this population requires further investigation.

Purpose of the Study:

• To evaluate the effect of transdermal estradiol therapy on bone mineral density in men with prostate cancer.
• To assess the potential of transdermal estradiol in mitigating ADT-induced bone loss.
• To determine if transdermal estradiol can improve BMD in men at risk for osteoporotic fractures.

Main Methods:

• A cohort of 20 patients with newly diagnosed prostate cancer received transdermal estradiol patches.
• Bone mineral density was measured using dual-energy x-ray absorptiometry (DXA) at the lumbar spine and proximal femur.
• Measurements were correlated with CT and isotope bone scan findings at 6-month intervals.

Main Results:

• Significant increases in BMD were observed across all measured regions after 1 year of transdermal estradiol therapy.
• Lumbar spine BMD increased by 3.60% (p=0.055), femoral neck by 2.19% (p=0.055), Ward's region by 3.76% (p=0.008), and total hip by 1.90% (p=0.031).
• Four out of 12 osteoporotic sites showed improvement based on WHO grading, with all other sites trending towards better classification.

Conclusions:

• Transdermal estradiol therapy effectively protects against bone loss in men undergoing treatment for prostate cancer.
• This therapy demonstrates potential for improving bone density and reducing osteoporotic fracture risk.
• Transdermal estradiol represents a promising therapeutic option for managing bone health in prostate cancer patients.